改造氨基酸摄取或分解代谢促进CAR-T细胞适应肿瘤环境
肿瘤细胞与T细胞竞争微环境中的氨基酸。研究者让CAR-T细胞同时表达SLC7A5或SLC7A11氨基酸转运体,在低色氨酸或胱氨酸条件下增殖增加且不损失杀伤力、不增加耗竭;转录组与表型分析显示下游精氨酸酶表达与活性上调,进一步构建表达精氨酸酶1/精氨酸酶2的CAR-T细胞,增殖与抗肿瘤活性增强。
要点
- 表达SLC7A5或SLC7A11转运体的CAR-T细胞在低色氨酸或胱氨酸条件下增殖增加,CAR细胞毒性未下降、耗竭未增加。
- 转录组与表型分析显示SLC7A5/SLC7A11修饰的CAR-T细胞上调细胞内精氨酸酶表达与活性。
- 表达功能性精氨酸酶1/精氨酸酶2的下一代CAR-T细胞增殖与抗肿瘤活性增强。
核心结论
- CAR-T细胞可被改造以适应肿瘤的氨基酸代谢微环境,该屏障此前已被认识但尚未被解决。
研究设计与样本
- 研究对T细胞进行改造,使其与CAR同时表达SLC7A5或SLC7A11跨膜氨基酸转运体,并进行转录组与表型分析。
- 进一步构建并表型分析表达功能性精氨酸酶1/精氨酸酶2的CAR-T细胞。
主要发现
- 转运体修饰使CAR-T细胞在低色氨酸或胱氨酸条件下增殖增加,且无CAR细胞毒性丧失或耗竭增加。
- 转录组与表型分析显示SLC7A5/SLC7A11修饰的CAR-T细胞上调细胞内精氨酸酶表达与活性。
- 表达功能性精氨酸酶1/精氨酸酶2的CAR-T细胞增殖与抗肿瘤活性增强。
关键数值与推荐
- 原文未报告具体数值、阈值或统计量。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer cells take up amino acids from the extracellular space to drive cell proliferation and viability. Similar mechanisms are applied by immune cells, resulting in the competition between conventional T cells, or indeed chimeric antigen receptor (CAR) T cells and tumor cells, for the limited availability of amino acids within the environment. We demonstrate that T cells can be re-engineered to express SLC7A5 or SLC7A11 transmembrane amino acid transporters alongside CARs. Transporter modifications increase CAR T-cell proliferation under low tryptophan or cystine conditions with no loss of CAR cytotoxicity or increased exhaustion. Transcriptomic and phenotypic analysis reveals that downstream, SLC7A5/SLC7A11-modified CAR T cells upregulate intracellular arginase expression and activity. In turn, we engineer and phenotype a further generation of CAR T cells that express functional arginase 1/arginase 2 enzymes and have enhanced CAR T-cell proliferation and antitumor activity. Thus, CAR T cells can be adapted to the amino acid metabolic microenvironment of cancer, a hitherto recognized but unaddressed barrier for successful CAR T-cell therapy.
引用
- Panetti S, McJannett N, Fultang L, et al. Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment. Blood Adv. 2023. PMID: 36521029. doi:10.1182/bloodadvances.2022008272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。